Ophthalmic Drug Development and Delivery

Venue: San Diego

Location: San Diego, United States

Event Date/Time: Sep 20, 2005
Report as Spam

Description

Age-related diseases have become more widespread. One barometer of this increasing life span is the increase in incidence and prevalence of ocular diseases such as glaucoma and age related macular degeneration (AMD), leading causes of blindness in those over 50 years of age. Visual impairment resulting from these diseases directly adversely affects activities of daily living and quality of life in later years.

Recent breakthroughs in novel therapies have heightened interest in developing other ophthalmic drugs because of their success in achieving clinically relevant efficacy and safety endpoints in clinical trials. As innovators seek to build upon the success of these and other therapeutic agents in order to better meet patient needs, this conference was developed to facilitate this process by bringing key opinion leaders together in order to present and discuss current trends in ophthalmic drug development.

This conference will present and discuss important drug development advances and challenges including:
Early efficacy in vitro or in vivo models used to characterize the drug candidate
Glaucoma models
Angiogenesis models
Important formulation approaches for optimal drug delivery to the eye
Drug delivery to front of the eye
Drug delivery to back of the eye
Novel drug delivery approaches
Distinct requirements for ocular PK assessments early in the drug selection/screening process
Anatomical/physiological differences between select animal models used for efficacy, PK and safety characterization of ophthalmics
Highlights of anticipated toxicology programs for support of clinical studies for ophthalmics
Insights on expected clinical study design such as issues of masking for complex ocular drug delivery approaches, etc., and relevant or non-relevant efficacy/safety endpoints in clinical studies for ocular diseases with particular focus on:
Glaucomas
Ocular neovascular diseases (AMD/DME, etc.)

Venue